Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
Accept Policy
Change cookie settings
EmailIphone Application    Posted: 16th August 2019
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Stem cell treatment a ‘breakthrough’ for equine lameness
“Arti-Cell® Forte contains stem cells that have been chondrogenically induced and therefore primed to develop into the cartilage cell lineage".
Arti-Cell Forte is the first stem cell-based medicine to receive marketing authorisation

The first stem cell-based medicine to receive marketing authorisation for the treatment of equine lameness has been launched by Boehringer Ingelheim.

Hailed as a ‘breakthrough medicine’ for degenerative joint disease in horses, Arti-Cell Forte is the first ‘ready-to-use’ stem cell-based product to be licensed in any veterinary species. It is also the only stem cell treatment to contain induced cells, marking a significant step in stem cell therapies and medicine as a whole.

“Arti-Cell® Forte contains stem cells that have been chondrogenically induced and therefore primed to develop into the cartilage cell lineage,” explained DR Amy Scott MRCVS, Boehringer Ingehlheim’s performance horse portfolio manager.

“Studies have shown that chondrogenically induced stem cells demonstrate an enhanced clinical outcome compared to un-induced stem cells in the treatment of joint disease in horses. This makes Arti-Cell® Forte a highly targeted and effective treatment for cartilage damage associated with degenerative joint disease.”

The medicine is available to veterinary practitioners direct from Boehringer Ingelheim. It is stored at ultra-low temperatures to maintain its two-year shelf life, either frozen at -70 ⁰C to -90 ⁰C (dry ice, -80 ⁰C freezer) or -196 ⁰C (liquid nitrogen) until immediately before injecting. 

Full training on storage and administration of the medicine is available from the Boehringer via face-to-face CPD at practice meetings or specific CPD events. For more information about these events, email vetenquiries@boehringer-ingelheim.com 

Become a member or log in to add this story to your CPD history

BEVA gives vets access to free membership for three months

News Story 1
 BEVA has announced that it is cutting membership renewal charges for the next three months in order to support all veterinary professionals during the COVID-19 pandemic.

Memberships for all existing BEVA members will be extended until 30 June 2020. Veterinary professionals who are not members of BEVA will also be able to sign up for a free membership until 30 June 2020.

BEVA president Tim Mair said: "In this extraordinary time of global crisis our profession, as with many industries, is under immense pressure. By offering free membership we are giving equine vets easy access to a wealth of supportive resources and online CPD."

To sign up please visit the BEVA website.

Image (c) BEVA. 

Click here for more...
News Shorts
BSAVA rolls out CPD resources and benefits in absence of Congress

A package of CPD resources and benefits are set to be rolled out on BSAVA's social media channels over the coming days in a bid to fill the gap left by the cancellation of BSAVA Congress.

The package includes a 10 discount voucher on all printed manuals and access to the BSAVA Library. BSAVA said that it will also be recording more than 100 hours of planned Congress lectures over the following weeks so that vets don't completely miss out on the Congress experience.

The resource, titled Congress on Demand will be ready in early May.